Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

Press Releases

Media

Media

  • Press Releases
  • Insights
Feb 11, 2019

Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer

Feb 4, 2019

Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference

Dec 12, 2018

Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma

Dec 3, 2018

Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition

Nov 29, 2018

Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer

Nov 26, 2018

Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer

Nov 13, 2018

Oncolytics Biotech® Announces Attendance of Upcoming Conferences

Nov 12, 2018

Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update

Nov 9, 2018

Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection

Nov 5, 2018

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights

    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...53
    © 2021 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap